Vincristine

• A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R… Pending
  2024-513445-37-00 Phase III 4 countries University Of Cologne
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 Phase II/III 10 countries University Medical Center Hamburg-Eppendorf
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 Phase III 5 countries GPOH gGmbH
• A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or … Recruiting
  2023-507899-47-00 Phase II 1 country Goethe University Frankfurt
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting
  2023-505377-32-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-… Recruiting
  2024-510616-73-00 Phase III 1 country Universitaetsklinikum Heidelberg AöR
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting
  2023-510516-39-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended
  2023-507286-25-00 Phase II 2 countries LYSARC
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended
  2024-516868-28-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended
  2023-509358-72-00 Phase III 9 countries Acerta Pharma B.V.
• A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL… Ended
  2024-515846-18-00 Phase I (FiH) 2 countries LYSARC
• HOVON 127 BL / SAKK 37/16: Phase III study comparing 2 treatments (R-CODOX-M/R-IVAC versus DA-EPOCH-R) in patients with Burkitt lymphoma Ended
  2023-503423-25-00 Phase III 2 countries Haemato Oncology Foundation For Adults Netherlands
• Trial investigating a personalized treatment, based on age and tumor characteristics , of newly diagnosed medullablastoma in patients that a… Ended
  2023-506193-12-00 Phase II 1 country European Organisation For Research And Treatment Of Cancer

Showing 1–14 of 14 trials